Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Chachoua Describes Clinical Trials Evaluating Immunotherapy in Lung Cancer

July 2nd 2014

Abraham Chachoua, MD, The Jay and Isabel Fine Associate Professor of Oncology, NYU Langone Medical Center, associate director, Cancer Services, Perlmutter Cancer Center at NYU Langone, discusses ongoing clinical trials at NYU that are evaluating immunotherapy in patients with lung cancer.

Dr. Galbraith Discusses the Development of AZD9291

July 1st 2014

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses the development of AZD9291 for lung cancer.

Enobosarm May Prevent Cancer-Induced Muscle Wasting in NSCLC

June 28th 2014

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

Alex Molasiotis, RN, PhD, on the Management on Breathlessness

June 27th 2014

Alex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.

50th Anniversary Report: Even More Known About Smoking, Cancer Connections

June 24th 2014

A recent report on the health consequences of smoking pored through the most recent data and several new findings about smoking and cancer.

Dr. Sequist Discusses the Efficacy of CO-1686 for NSCLC

June 23rd 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the efficacy of CO-1686 for the treatment of non-small cell lung cancer.

Docetaxel May Cause Intoxication, FDA Warns

June 20th 2014

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

Dr. Sequist Discusses Adverse Events Associated With CO-1686

June 16th 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer.

Dr. Kim Discusses Detecting EGFR and KRAS Mutations from Cell-Free Plasma DNA of NSCLC Patients

June 16th 2014

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of improved and complete enrichment co-amplification at lower denaturation temperature method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of patients with non-small cell lung cancer (NSCLC).

Dr. Piperdi Discusses RICTOR Amplification in Lung Cancer

June 12th 2014

Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.

Continuing Afatinib Beyond Progression Improves PFS in Metastatic NSCLC

June 10th 2014

Continuing EGFR inhibition beyond progression with afatinib plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.

Pembrolizumab Induces Robust Responses in PD-L1-positive NSCLC

June 6th 2014

The anti-PD-1 humanized antibody pembrolizumab has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive NSCLC.

Necitumumab Delivers Rare Survival Benefit in Squamous NSCLC

June 6th 2014

Adding necitumumab to standard of care with gemcitabine-cisplatin significantly improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small-cell lung cancer of squamous histology.

Dr. Ramalingam on the Results of the Phase III REVEL Study in NSCLC

June 5th 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses the results of the phase III REVEL study in NSCLC.

Dr. Curran on the Effect of Clinical Trial Enrollment on NSCLC Patients

June 4th 2014

Walter J. Curran, Jr, MD, discusses a report that examined the effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation.

Dr. Spigel Discusses MPDL3280A Development in Lung Cancer

June 3rd 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials involving MPDL3280A in lung cancer.

CO-1686 Continues to Show Promising Results in Treatment-Resistant NSCLC

June 1st 2014

The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).

Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC

June 1st 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Ramucirumab Modestly Improves Survival in Advanced NSCLC

June 1st 2014

Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer.

2nd Annual Giants of Cancer Care Awards Honor Leading Researchers

May 30th 2014

The ballots are in, and 16 leading researchers whose discoveries have propelled the field of cancer treatment forward will be honored during the 2014 Giants of Cancer Care award ceremony on May 30 at Riva Restaurant on Navy Pier in Chicago.

NEXT PAGE
PREVIOUS PAGE